Figure 5.

MRD sensitivity threshold. Association of MRD negativity with PFS (A) and OS (B) outcomes in various subgroups of patients with MM. ^aP vs MRD positive. ^bMRD sensitivity thresholds at 10⁻⁴, 10⁻⁵, and 10⁻⁶ were defined as 1 MM cell per 10 000, 100 000, and 1 000 000 nucleated cells, respectively. ^cGenetic abnormalities reported in high-risk patients in this meta-analysis were predominantly defined as the presence of t(4,14), t(14,16), and/or del(17p). ^dStandard risk was defined as the absence of genetic abnormalities seen in high-risk patients. ^eOnly includes studies with MRD sensitivity thresholds at 10⁻⁵ and 10⁻⁶; in studies including 10⁻⁴, 10⁻⁵, and 10⁻⁶ MRD sensitivity thresholds, the HR estimates for PFS and OS were 0.41 (95% CI, 0.36-0.46) and 0.49 (95% CI, 0.42-0.57), respectively. ^fIncludes studies that reported immunophenotypic CR, stringent CR, or near CR. ^gDoes not overlap with CR. ^hMRD assessed at 100 days post-ASCT. ⁱMRD assessed at 12 months after start of maintenance therapy.